Diagnos Inc (TSE:ADK) has released an update.
Diagnos Inc. is ramping up its efforts to secure Health Canada and FDA approvals for four new AI analysis modules designed to enhance early detection of various retinopathies, targeting commercial launch in Q3 2024. The modules will support healthcare professionals by utilizing AI for improved analysis of eye-related diseases, thus potentially increasing the company’s revenue. Additionally, Diagnos is working towards ISO 27001 Cyber Security certification to meet customer and prospect requirements.
For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.
